About this document

SH 2 by Camila Nunes is a document available to read on EtoBox.

This study investigates canine histiocytic sarcoma (HS) and hemophagocytic histiocytic sarcoma (HHS), revealing a high prevalence of PTPN11/SHP2 mutations and KRAS mutations in these cancers. The research indicates that cobimetinib, a MEK inhibitor, shows promise in treating these aggressive cancers, with IC50 values suggesting effective concentrations for treatment. The findings enhance understanding of the molecular pathology of HS and HHS and support further clinical trials for cobimetinib in dogs.

Author

Camila Nunes

Language

EN